SecBot SecBot
SECBOTREPLAY Home › Report › IMCR

IMCR · Immunocore reported strong financial results for Q4 and full year 2025,…

Immunocore Holdings plc · 8-K filed Feb 25, 2026 at 07:30 ET

At the news

BULLISHIMPACT 7/10

8-K filed Feb 25, 2026 at 07:30 ET

Immunocore reported strong financial results for Q4 and full year 2025, with KIMMTRAK net sales of $104.5 million and $400.0 million respectively, representing 24% and 29% year-over-year growth. The company reduced its net loss from $51.1 million in 2024 to $35.5 million in 2025 despite increased R&D spending, and ended the year with $864.2 million in cash. Management expects moderating revenue growth in 2026 as it awaits key clinical data readouts.

  • KIMMTRAK net sales were $104.5 million in Q4 2025 (up 24% YoY) and $400.0 million for full year 2025 (up 29% YoY)
  • Net loss improved to $35.5 million in 2025 from $51.1 million in 2024 despite higher R&D expenses
  • Cash, cash equivalents and marketable securities totaled $864.2 million as of December 31, 2025
  • R&D expenses increased to $274.9 million in 2025 from $222.2 million in 2024 due to autoimmune programs and Phase 3 trials

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access